Analysts Set Carisma Therapeutics, Inc. (NASDAQ:CARM) Target Price at $4.94

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have earned a consensus rating of “Hold” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $4.94.

Several research analysts have issued reports on the company. D. Boral Capital cut their price target on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, December 9th. EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Baird R W cut Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. HC Wainwright reiterated a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Finally, Evercore ISI restated an “in-line” rating and issued a $0.70 target price (down previously from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th.

Hedge Funds Weigh In On Carisma Therapeutics

Several large investors have recently modified their holdings of the business. Barclays PLC boosted its holdings in Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after buying an additional 549,290 shares during the period. Wexford Capital LP boosted its holdings in shares of Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Carisma Therapeutics in the second quarter valued at $40,000. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Stock Down 0.6 %

Shares of Carisma Therapeutics stock opened at $0.47 on Monday. The stock’s 50-day moving average is $0.70 and its 200 day moving average is $0.94. Carisma Therapeutics has a one year low of $0.38 and a one year high of $2.94. The firm has a market cap of $19.67 million, a price-to-earnings ratio of -0.30 and a beta of 1.44. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23.

Carisma Therapeutics (NASDAQ:CARM) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). The company had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. Equities research analysts anticipate that Carisma Therapeutics will post -1.32 EPS for the current year.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.